Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.

Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA.

Mol Cancer Ther. 2018 Aug 10. doi: 10.1158/1535-7163.MCT-18-0091. [Epub ahead of print]

PMID:
30097487
2.

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.

Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA.

Sci Transl Med. 2017 Nov 8;9(415). pii: eaan0401. doi: 10.1126/scitranslmed.aan0401.

PMID:
29118259

Supplemental Content

Loading ...
Support Center